Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) is set to release its earnings data before the market opens on Thursday, August 3rd. Analysts expect Alnylam Pharmaceuticals to post earnings of ($1.71) per share for the quarter. Alnylam Pharmaceuticals has set its FY 2023 guidance at EPS.Parties interested in listening to the company’s conference call can do so using this link.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.97) by $0.57. The business had revenue of $319.29 million for the quarter, compared to analyst estimates of $312.53 million. Alnylam Pharmaceuticals had a negative return on equity of 1,287.80% and a negative net margin of 93.13%. The firm’s revenue was up 49.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($2.00) EPS. On average, analysts expect Alnylam Pharmaceuticals to post $-7 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
Alnylam Pharmaceuticals Price Performance
Shares of ALNY opened at $194.94 on Thursday. Alnylam Pharmaceuticals has a fifty-two week low of $135.46 and a fifty-two week high of $242.97. The firm has a market capitalization of $24.28 billion, a PE ratio of -22.43 and a beta of 0.48. The company’s 50-day moving average is $194.65 and its 200-day moving average is $203.28.
Institutional Investors Weigh In On Alnylam Pharmaceuticals
Several institutional investors have recently bought and sold shares of the stock. KB Financial Partners LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 1st quarter worth $35,000. Northwestern Mutual Wealth Management Co. increased its stake in Alnylam Pharmaceuticals by 59.4% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 373 shares of the biopharmaceutical company’s stock valued at $89,000 after buying an additional 139 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of Alnylam Pharmaceuticals during the 1st quarter worth approximately $103,000. 1832 Asset Management L.P. purchased a new stake in shares of Alnylam Pharmaceuticals during the first quarter valued at approximately $88,000. Finally, Manatuck Hill Partners LLC bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth $238,000. Institutional investors own 94.43% of the company’s stock.
Wall Street Analyst Weigh In
ALNY has been the topic of several analyst reports. Royal Bank of Canada reduced their target price on Alnylam Pharmaceuticals from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Tuesday. BMO Capital Markets raised shares of Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $200.00 to $250.00 in a report on Friday, May 5th. StockNews.com upgraded Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, July 21st. Morgan Stanley boosted their price target on Alnylam Pharmaceuticals from $205.00 to $210.00 and gave the stock an “equal weight” rating in a report on Tuesday, April 4th. Finally, HC Wainwright decreased their price target on shares of Alnylam Pharmaceuticals from $415.00 to $405.00 and set a “buy” rating for the company in a research report on Tuesday. Four research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $251.00.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company’s pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Alnylam Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Alnylam Pharmaceuticals wasn’t on the list.
While Alnylam Pharmaceuticals currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Do you expect the global demand for energy to shrink?! If not, it’s time to take a look at how energy stocks can play a part in your portfolio.
